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Abstract. 
 
In response to extracellular stimuli, mitogen-
activated protein kinase (MAPK, also known as ERK), 
which localizes to the cytoplasm in quiescent cells, 
translocates to the nucleus and then relocalizes to the 
cytoplasm again. The relocalization of nuclear MAPK 
to the cytoplasm was not inhibited by cycloheximide, 
conﬁrming that the relocalization is achieved by nu-
clear export, but not synthesis, of MAPK. The nuclear 
export of MAPK was inhibited by leptomycin B 
(LMB), a speciﬁc inhibitor of the nuclear export signal 
(NES)-dependent transport. We have then shown that 
MAP kinase kinase (MAPKK, also known as MEK), 
which mostly localizes to the cytoplasm because of its 
having NES, is able to shuttle between the cytoplasm 
and the nucleus constantly. MAPK, when injected into 
the nucleus, was rapidly exported from the nucleus by 
coinjected wild-type MAPKK, but not by the NES-dis-
rupted MAPKK. In addition, injection of the fragment 
corresponding to the MAPK-binding site of MAPKK 
into the nucleus, which would disrupt the binding of 
MAPK to MAPKK in the nucleus, signiﬁcantly inhib-
ited the nuclear export of endogenous MAPK. Taken 
together, these results suggest that the relocalization of 
nuclear MAPK to the cytoplasm involves a MAPKK-
dependent, active transport mechanism.
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Abbreviations used in this paper: 
 
CHX, cycloheximide; DAPI, 4
 
9
 
,6-
diamidino-2-phenylindole; LMB, leptomycin B; MAPK, mitogen-acti-
vated protein kinase; MAPKK, MAPK kinase; NES, nuclear export sig-
nal; TPA, 12-
 
O
 
-tetra decanoyl phorbol myristate acetate.
 
Introduction
 
The mitogen-activated protein kinase (MAPK, also known
 
as ERK)
 
1
 
 cascade is a central signal transduction pathway
that is activated by growth factors, and is known to be in-
volved in diverse cellular functions (Sturgill and Wu, 1991;
Thomas, 1992; Blenis, 1993; Davis, 1993; Nishida and Go-
toh, 1993; Marshall, 1994; Lewis et al., 1998; Robinson and
Cobb, 1997). In response to a wide variety of extracellular
stimuli, three classes of protein kinases, MAP kinase ki-
nase kinase (MAPKKK), MAP kinase kinase (MAPKK,
also known as MEK) and MAPK, are sequentially acti-
vated. Activation of MAPK leads to its translocation from
the cytoplasm to the nucleus, where MAPK phosphory-
lates and activates several nuclear targets such as tran-
scription factors (Chen et al., 1992; Gonzalez et al., 1993;
Lenormand et al., 1993). Nuclear localization of MAPK is
transient, however, and MAPK relocalizes to the cyto-
plasm to prepare for the next activation.
To date, a number of reports have addressed regulatory
mechanisms of the nuclear translocation of MAPK. We
have previously demonstrated that MAPKK (MEK1 or
MEK2), a direct activator of MAPK (ERK1 or ERK2),
acts as a cytoplasmic anchor of MAPK (Fukuda et al.,
1997a). MAPKK apparently localizes to the cytoplasm ir-
respective of its activation state (Lenormand et al., 1993;
Zheng and Guan, 1994; Moriguchi et al., 1995), and this is
due to its nuclear export signal (NES) at its NH
 
2
 
 terminus
(Fukuda et al., 1996). Upon stimulation, MAPK disso-
ciates from MAPKK (Fukuda et al., 1997a). The disso-
ciation requires tyrosine phosphorylation of MAPK by
MAPKK (Adachi et al., 1999). Khokhlatchev et al. (1998)
have demonstrated that homodimerization of MAPK,
which is induced by phosphorylation of MAPK, is an im-
portant mechanism for nuclear translocation of MAPK. 
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We have then shown that dimeric MAPK enters the nu-
cleus by using an active transport mechanism, whereas
MAPK can also enter the nucleus by passive diffusion as a
monomer (Adachi et al., 1999). Moreover, Lenormand et al.
(1998) proposed that activation of the MAPK cascade
leads to neosynthesis of nuclear anchoring protein for
MAPK, which seems to be required for sustained nuclear
retention of MAPK. MAPK then must relocalize to the cy-
toplasm again to prepare for the next stimulation. How-
ever, so far, there have been no reports directly examining
how MAPK relocalizes to the cytoplasm after its nuclear
entry.
Here we first show evidence that the relocalization of
MAPK to the cytoplasm is achieved by nuclear export of
MAPK. Then, we have demonstrated that the nuclear ex-
port of MAPK is inhibited by LMB, a specific inhibitor of
the NES-dependent transport. MAPKK, which mostly lo-
calizes to the cytoplasm because of its NES, is shown to be
able to shuttle between the cytoplasm and the nucleus
constantly under normal conditions. While MAPKK is ex-
ported from the nucleus by the NES-dependent active
transport, its nuclear entry seems to be achieved by pas-
sive diffusion, since 
 
b
 
-gal-MAPKK, in which 
 
b
 
-galactosi-
dase was fused to the NH
 
2
 
 terminus of MAPKK to make
MAPKK too large to pass through a nuclear pore by diffu-
sion, could not enter the nucleus even in the presence of
LMB. Moreover, our result demonstrates that the export
of nuclear injected MAPK from the nucleus was rapidly
induced by nuclear coinjection of wild-type MAPKK, but
not by that of the NES-disrupted MAPKK. In addition,
nuclear injection of the NH
 
2
 
-terminal portion of MAPKK,
which contains the MAPK-binding site, inhibited the nu-
clear export of MAPK. Therefore, it is likely that MAPK
is exported from the nucleus to the cytoplasm by MAPKK.
Taken together, our findings suggest that MAPKK not
only acts as a cytoplasmic anchor of MAPK but also medi-
ates nuclear export of MAPK and, therefore, may be a
central regulator of subcellular localization of MAPK.
 
Materials and Methods
 
Cell Culture and Microinjection
 
Xenopus
 
 A6 cells and rat 3Y1 cells plated onto coverslips were cultured in
Leibovitz’s L-15 medium or DME supplemented with 10% FCS and anti-
biotics (100 U/ml penicillin and 0.2 mg/ml kanamycin), respectively. 
 
D
 
B-
Raf:ER cells (Pritchard et al., 1995) were cultured in DME without phe-
nol red supplemented with FCS, antibiotics, and 25 mM Hepes (pH. 7.4).
Microinjection was performed using an IM-188 microinjection apparatus
(Narishige). Samples were dissolved in injection buffer (20 mM Hepes-
KOH, pH 7.4, 120 mM KCl).
 
Cell Staining
 
Cells were fixed by the direct addition of formaldehyde (final concentra-
tion 3.7%) to the cell culture medium and then permeabilized with 0.5%
Triton X-100 in PBS for 5 min. The coverslips were incubated with pri-
mary antibodies at 4
 
8
 
C overnight, and then with the appropriate second-
ary antibodies at room temperature for 1 h. The primary antibodies and
dilutions used here were a rabbit antiserum to 
 
Xenopus
 
 MAPK (Fukuda
et al., 1997a; 1:200 dilution), a rabbit anti-ERK1 antibody (K-23; Santa
Cruz; 1:100) and a mouse monoclonal anti-HA antibody (12CA5, 1:200).
Cells were finally mounted in Mowiol and examined using a Zeiss Axio-
photo.
Figure 1. Relocalization of nuclear MAPK to the cytoplasm is
mediated by nuclear export. Staining images of cells with anti-
Xenopus MAPK antibody (a–e) or DAPI (f–j) are shown. A6
cells were serum starved for 36 h (a and f), and then stimulated
with 10% FCS for 4 h (b and g). Then cells were treated with
CHX (50 mg/ml) for 10 min, followed by deprivation of serum for
10 min in the presence of CHX (d and i), or cells were treated
with control buffer for 10 min and then deprived of serum for 10
min in the presence of the buffer (c and h). Incubation of cells
with CHX or buffer for 10 min alone did not change subcellular
distribution of MAPK (data not shown). In agreement with the
result of Lenormand et al. (1998), stimulation of cells with 10%
FCS for 4 h in the presence of CHX (50 mg/ml) did not induce nu-
clear accumulation of MAPK (e and j), indicating that CHX at
this concentration is effective. Experiments were performed
twice with similar results. 
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DNA Construction and Transfection
 
A BamHI-BglII fragment of 
 
Escherichia coli
 
 
 
b
 
-galactosidase gene
(Adachi et al., 1999) was subcloned into the BglII site of pSR
 
a
 
HA1 to
yield pSR
 
a
 
HA-
 
b
 
-gal. A BglII fragment of 
 
Xenopus
 
 MAPKK (Adachi
et al., 1999) is cloned into the BglII site of pSR
 
a
 
HA-
 
b
 
-gal, yielding
pSR
 
a
 
HA-
 
b
 
-gal-MAPKK. A BglII fragment of LA MAPKK obtained
from pSR
 
a
 
HA-LA MAPKK (Fukuda et al., 1996) was subcloned into
pET-28a (Novagen) to obtain pET-28a LA MAPKK.
 
Preparation of Recombinant Proteins
 
The fusion protein between GST and the NH
 
2
 
-terminal portion of
MAPKK (residues 1–60) with a disrupted NES (GST KK1-60 LA) was
prepared as described (Fukuda et al., 1997a). His-tagged MAPK and His-
tagged wild-type and NES-disrupted (LA) MAPKK were prepared as de-
scribed (Gotoh et al., 1994).
 
Results
 
Relocalization of Nuclear MAPK to the Cytoplasm Is 
Mediated by a Nuclear Export Mechanism
 
Nuclear translocation of MAPK is transient, although the
duration time in the nucleus varies depending on the cell
types and the stimuli used. Thus, nuclear MAPK should
relocalize to the cytoplasm. However, it is also possible
that nuclear MAPK is degraded and newly synthesized
MAPK appears in the cytoplasm. To test this possibility,
we examined the effect of a protein synthesis inhibitor cy-
cloheximide (CHX) on the relocalization of MAPK to the
cytoplasm. In A6 cells, nuclear accumulation of MAPK
(
 
Xenopus
 
 MPK1
 
 5 
 
ERK2) is most strongly induced after
4 h of stimulation with 10% FCS. Subsequent serum re-
moval triggers appearance of MAPK in the cytoplasm
and disappearance of nuclear MAPK. CHX was added to
the cultures 4 h after stimulation with serum. After a 10-
min incubation, cells were deprived of serum in the presence
of CHX, and then the cells were fixed 10 min later. The
indirect immunostaining of endogenous MAPK demon-
strated that MAPK relocalized to the cytoplasm even in
the presence of CHX (Fig. 1). Therefore, relocalization
of nuclear MAPK to the cytoplasm is mediated by a nu-
clear export mechanism, not by synthesis of MAPK in
the cytoplasm.
 
LMB Inhibits Nuclear Export of MAPK
 
We then tested the effect of LMB on the nuclear export of
MAPK. In 3Y1 cells, MAPK translocated to the nucleus
within 5 min after stimulation with TPA, and after 10 min
MAPK was exported from the nucleus (Fig. 2, TPA).
When LMB was added 5 min after TPA stimulation (i.e.,
when nuclear translocation of MAPK was achieved), sub-
sequent nuclear export of MAPK was strongly inhibited
(Fig. 2, TPA
 
1
 
LMB). Similar results were obtained in A6
cells (data not shown). As LMB is a specific inhibitor of
NES receptor (Fornerod et al., 1997; Fukuda et al., 1997b;
Figure 2. LMB inhibits the
nuclear export of MAPK.
3Y1 cells were serum starved
for 36 h. Then, the cells were
stimulated with TPA alone
(500 ng/ml, upper panels in
A, circles in B). LMB (0.4 ng/
ml) was added 5 min after
the addition of TPA (middle
panels in A, squares in B), or
only LMB without TPA
treatment was added (lower
panels in A, triangles in B).
Cells were fixed, and then
stained with anti-ERK1 anti-
body. The representative im-
ages are shown in A. (B)
Quantification of the data
from a representative experi-
ment. The percentages of
cells in which nuclear MAPK
staining was stronger than, or equal to, cytoplasmic MAPK staining are shown in each condition. 86–116 cells were examined in each
condition. Experiments were performed four times with similar results. 
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Ossareh-Nazari et al., 1997; Wolff et al., 1997), it is sug-
gested that the nuclear export of MAPK is mediated by
the NES-dependent active transport mechanism.
 
MAPKK Shuttles between the Cytoplasm and
the Nucleus
 
Because MAPK does not seem to have an NES-like se-
quence, we thought that some other NES-possessing mole-
cules may convey MAPK from the nucleus to the cyto-
plasm. As MAPKK has an NES at its NH
 
2
 
 terminus
(Fukuda et al., 1996) and specifically binds to MAPK
(Fukuda et al., 1997a), we hypothesized that MAPKK is a
possible carrier of MAPK. To perform this function, how-
ever, MAPKK must enter the nucleus at least transiently,
although MAPKK mostly localizes to the cytoplasm (Le-
 
normand et al., 1993; Zheng and Guan, 1994; Moriguchi
et al., 1995). To examine whether MAPKK is able to shut-
tle between the cytoplasm and the nucleus, we carried out
the following experiment. In quiescent 3Y1 cells, HA-
tagged MAPKK was expressed by the plasmid injection,
and anti-HA antibody was injected into the nucleus. Then,
location of the injected anti-HA antibody was examined.
In the absence of HA-MAPKK, the anti-HA antibody re-
mained in the nucleus, while in the presence of the ex-
pressed HA-MAPKK, most of anti-HA antibody became
detected in the cytoplasm (Fig. 3, A and B). These results
are interpreted as indicating that HA-MAPKK expressed
in the cytoplasm enters the nucleus where HA-MAPKK
binds to anti-HA antibody, and then the HA-MAPKK/
anti-HA antibody complex is exported from the nucleus.
Therefore, MAPKK has now been shown to shuttle be-
 
Figure 3
 
. MAPKK shuttles between the cytoplasm and the nucleus. (A and B) 3Y1 cells were serum starved for 48 h. Then, the nuclei
were injected with anti-HA antibody (
 
a
 
HA, 20.0 mg/ml) or control IgG (IgG, 20.4 mg/ml) together with the plasmid harboring HA-
tagged MAPKK (HA-MAPKK, 150 
 
m
 
g/ml) or the corresponding amount of an empty vector (SR
 
a
 
), all together with FITC-labeled
dextran (FITC-Dextran, 800 
 
m
 
g/ml). 5 or 16 h after injection, cells were fixed and stained with Cy3-labeled anti–mouse IgG. The typical
images at 16 h after injection are shown in A. (B) Quantification of the data from two independent experiments for nuclear injection of
anti-HA antibody (
 
a
 
HA) with SR
 
a
 
 or the HA-MAPKK plasmid. The cells were classified into four categories in terms of location of
the injected 
 
a
 
HA antibody (
 
5 
 
Cy3 staining intensity): N
 
 .. 
 
C, staining intensity in the nucleus (N) is much stronger than that in the cy-
toplasm (C); N
 
 . 
 
C, N is stronger than C; N
 
 # 
 
C, C is equal to or stronger than N; N
 
 ,, 
 
C, C is much stronger than N (the 
 
a
 
HA is al-
most completely exported from the nucleus). 56–295 cells were examined in each condition in one experiment. Grey bars, 5 h after in-
jection; black bars, 16 h after injection. Under the conditions used, expression of HA-MAPKK, which was revealed by anti-HA staining
in another series of experiments, occurred in almost all the plasmid-injected cells within 4 h. The export of the nuclear injected 
 
a
 
HA
from the nucleus was clearly detected even 5 h after the nuclear injection of the HA-MAPKK plasmid (see this figure), so the shuttling
of HA-MAPKK may occur frequently. (C) 
 
D
 
B-Raf:ER cells (Pritchard et al., 1995) were transfected with either SR
 
a
 
HA-MAPKK or
SR
 
a
 
HA-
 
b
 
-gal-MAPKK together with pCDNA3 MAPK. 16 h later cells were treated with LMB (LMB, 20 ng/ml) and/or 4-hydroxyta-
moxifen (4-HT, 1 
 
m
 
M), which activates 
 
D
 
B-Raf, for 5 h. Cells were then fixed and stained with anti-HA antibody. Experiments were
performed twice with similar results.
Figure 4. Nuclear export of MAPK protein is induced by nuclear coinjection of wild-type MAPKK, but not by that of NES-disrupted
MAPKK. The nuclei of 3Y1 cells were injected with TRITC-BSA and His-tagged MAPK protein (5.0 mg/ml) without (Control) or with
His-tagged wild-type MAPKK protein (5.0 mg/ml; His-WT MAPKK) or His-tagged, NES-disrupted MAPKK protein (5.0 mg/ml; His-LA
MAPKK). 5 min after injection, cells were fixed and stained with anti-MAPK antibody. The representative images are shown in A. (B)
Quantification of the data from three independent experiments. The percentages of cells which showed stronger MAPK fluorescence
intensity in the cytoplasm than in the nucleus are shown in each condition. 76–272 cells were examined in each condition in one experi-
ment. 
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tween the cytoplasm and the nucleus constantly. More-
over, our finding with the indirect immunofluorescent cell
staining method that nuclear entry of MAPKK can be
clearly detected as early as 10 min after LMB treatment of
the cells (Fukuda et al., 1997b) is consistent with the idea
that MAPKK is shuttling between the cytoplasm and the
nucleus constantly and suggests that the shuttling is occur-
ring rapidly.
Previous studies have suggested that nuclear entry of
MAPKK is enhanced in a stimulus-dependent manner, al-
though in normal conditions it is not apparent since
MAPKK is immediately exported to the cytoplasm by
means of its NES (Jaaro et al., 1997; Tolwinski et al.,
1999). This possible mechanism is consistent with our idea
of MAPKK shuttling. To examine the possible involve-
ment of active nuclear import mechanisms in the regulated
nuclear entry of MAPKK, we used 
 
b
 
-gal-MAPKK in
which 
 
b
 
-galactosidase is fused to the NH
 
2
 
 terminus of
MAPKK to make MAPKK too large to pass through a nu-
clear pore by diffusion. As shown in Fig. 3 C, 
 
b
 
-gal-
MAPKK did not translocate to the nucleus even in the
presence of LMB and the stimulus that activates the
MAPK cascade. Therefore, the regulated nuclear entry of
MAPKK, if present, may not be achieved through active
nuclear import mechanisms. In fact, cooling of cells or
deprivation of ATP induced nuclear entry of MAPKK
(Adachi et al., 1999; data not shown). This also supports
our idea that MAPKK enters the nucleus constantly by
passive diffusion and is always exported actively by the
NES-dependent, active mechanism.
 
Nuclear Injection of MAPKK with MAPK Induces 
Nuclear Export of MAPK
 
If MAPKK indeed takes MAPK out of the nucleus, then
nuclear export of MAPK should be accelerated by the
presence of excess MAPKK in the nucleus. To test this
idea, we injected recombinant MAPK protein into the nu-
clei of 3Y1 cells together with or without recombinant
MAPKK protein and then examined the subcellular distri-
bution of injected MAPK protein 5 min after injection.
When injected alone, MAPK stayed in the nucleus (Fig. 4,
Control). In contrast, coinjection of wild-type MAPKK
significantly induced the nuclear export of MAPK (Fig. 4,
His-WT MAPKK). Importantly, NES-disrupted MAPKK
did not induce the nuclear export of MAPK at all (Fig. 4,
His-LA MAPKK). These results clearly demonstrate that
MAPKK is able to carry MAPK out of the nucleus by us-
ing the NES of MAPKK.
 
Nuclear Export of MAPK Is Blocked by Inhibition of 
the Binding between MAPKK and MAPK in
the Nucleus
 
If MAPKK is necessary for nuclear export of MAPK,
then the inhibition of the binding between MAPK and
MAPKK in the nucleus would result in the blockade of the
nuclear export of MAPK. To inhibit the binding, we in-
jected a peptide fragment (GST-KK 1-60 LA) that corre-
sponds to the MAPK-binding site of MAPKK (the fusion
Figure 5. Nuclear export of MAPK
is significantly inhibited by inhibit-
ing its binding to MAPKK in the
nucleus. A6 cells were serum
starved for 36 h, and stimulated
with 10% FCS for 4 h. Then, the
nuclei were injected with GST (15.0
mg/ml) or the GST fusion protein
of the NH2-terminal 1–60 residues of MAPKK with a disrupted NES (GST-KK 1-60 LA, 16.0 mg/ml) together with TRITC-BSA. Then,
the culture medium was replaced by the serum-free medium. 10 min after the serum removal, cells were fixed and stained with anti-
MAPK antibody. The typical images are shown in A. (B) Quantification of the data from three independent experiments. The percent-
ages of cells which showed stronger MAPK staining in the nucleus than in the cytoplasm are shown in each condition. 133–262 cells
were examined in each condition in one experiment. 
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protein between GST and the NH
 
2
 
-terminal region of
MAPKK, residues 1–60, in which the NES is disrupted)
into the nuclei of A6 cells. It has been shown that MAPK
binds to the residues 1–32 of MAPKK (Bardwell et al.,
1996; Fukuda et al., 1997a). Thus, microinjection of the
fragment into the nuclei was performed 4 h after stimula-
tion with serum. And then, 10 min after serum removal,
the cells were fixed. The indirect immunostaining demon-
strated that injection of GST-KK 1-60 LA, but not that of
GST, inhibited the nuclear export of endogenous MAPK
(Fig. 5, A and B). Although we cannot exclude the possi-
bility that some other molecule which can bind to the
MAPKK binding region of MAPK might be a carrier of
MAPK, the above result strongly suggests that the nuclear
export of MAPK is mediated by MAPKK.
 
Discussion
 
This study is the first to deal with the mechanism of the
nuclear export process of MAPK, and suggests that nu-
clear export of MAPK is mediated by MAPKK. Our re-
sults show that (a) relocalization of nuclear MAPK to the
cytoplasm is achieved by a nuclear export mechanism; (b)
LMB, a specific inhibitor of NES-dependent active trans-
port, inhibits nuclear export of MAPK; (c) MAPKK,
which possesses an NES, shuttles between the cytoplasm
and the nucleus; (d) coinjection of MAPKK with MAPK
into the nucleus rapidly induces the nuclear export of
MAPK; and (e) inhibition of the binding between
MAPKK and MAPK in the nucleus prevents the nuclear
export of MAPK. From these results, we suggest that
MAPKK has a role in conveying MAPK from the nucleus
to the cytoplasm, although we cannot rule out completely
the possibility that some other molecule with an NES is a
carrier of MAPK.
Importantly, if MAPKK is a carrier of MAPK for its ex-
port, dephosphorylated MAPK is selectively exported to
the cytoplasm, because only dephosphorylated MAPK
binds to MAPKK (Adachi et al., 1999). Consistent with
this, our immunostaining experiment with anti-active
MAPK antibody and anti-MAPK antibody showed that
active MAPK did not relocalize to the cytoplasm after the
nuclear entry in response to TPA stimulation in 3Y1 cells
and became deactivated in the nucleus, while the bulk of
MAPK relocalized to the cytoplasm (data not shown).
Moreover, the report of Khokhlatchev et al. (1998) dem-
onstrated that thiophosphorylated MAPK, which was in-
jected into the nucleus remained in the nucleus for a long
time, whereas unphosphorylated MAPK relocalized to the
cytoplasm immediately. This is also in agreement with our
model. This model also suggests that nuclear export of
MAPK does not have a role in shutting off the MAPK
pathway, because subcellular distribution of only inactive
MAPK can be controlled by the export mechanism. So nu-
clear export of MAPK may function to restore cytoplas-
mic pool of activatable MAPK for the next stimulation
and, therefore, to ensure sustained and continuous activa-
tion of the MAPK cascade.
In summary, we have demonstrated that nuclear export
of MAPK involves a MAPKK-dependent, active transport
mechanism. Because inactivated MAPK preferentially
binds to MAPKK, MAPK, once deactivated in the nu-
 
cleus, would be rapidly excluded from the nucleus. There-
fore, this mechanism may work to localize inactive MAPK
to the cytoplasm selectively, thus making the cells respond
to extracellular stimuli rapidly and continuously.
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